CAPR stock price: Why is Capricor Therapeutics stock surging over 293% today?

CAPR stock: Shares of Capricor Therapeutics Inc surged on Wednesday, rallying more than 293% following the release of topline results from its pivotal Phase 3 HOPE-3 trial.

CAPR Stock Today Soars on Phase 3 Trial Success

The study evaluated Deramiocel, the company’s experimental cell therapy for Duchenne muscular dystrophy (DMD), a severe genetic disorder that causes progressive muscle weakness, primarily in boys, as per a report.

HOPE-3 Trial Design: How Capricor Therapeutics Tested Deramiocel in 106 Participants

The HOPE-3 trial, which included 106 participants across 20 US centers, administered intravenous Deramiocel infusions of 150 million cells every three months over a 12-month period, as per a Benzinga report.


The average age of participants was approximately 15 years, and all continued their standard corticosteroid therapy. At the start of the trial, about 90% were on cardiac medications, and over 75% already had clinical cardiomyopathy.

ALSO READ: MSFT stock price: Microsoft stock falls today after slashing AI sales targets – what investors need to know

Deramiocel Shows Promising Results for Muscle and Heart Function in DMD Patients

Results showed that nearly 54% of patients experienced slowing of skeletal muscle disease progression, while around 91% demonstrated improvement in heart function.

Expert Insights: What Investigators Say About Capricor Therapeutics' HOPE-3 Trial Outcomes

Craig McDonald, an investigator on the HOPE-3 trial study, said that, “The HOPE-3 study is the first-ever Phase 3 trial in a largely non-ambulatory population with DMD to successfully meet its primary endpoint and to support the development of an innovative therapy over many years, with this level of impact has been a profound privilege,” as quoted by Benzinga.

Jonathan Soslow, Professor of Pediatrics (Cardiology) at Vanderbilt University Medical Center, explained that, “The statistically and clinically significant preservation of left ventricular ejection fraction in patients treated with Deramiocel observed in HOPE-3 underscores the potential of Deramiocel to address one of the most critical aspects of the disease,” as quoted in the Benzinga report.

ALSO READ: FDA cheese recall: Over 1.5 million bags may contain metal fragments – check affected brands and what to do next

FDA Background: Previous Complete Response Letter and Regulatory Challenges For Capricor

The news comes months after Capricor received a Complete Response Letter from the FDA for its previous Biologics License Application, which cited a need for additional clinical data.

FAQs

Why did CAPR stock surge?
Investors reacted to the positive Phase 3 HOPE-3 results, pushing shares up over 293%.

What was the HOPE-3 trial?
A Phase 3 study testing Deramiocel in 106 participants across 20 U.S. centers.